Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
**Background:** Alopecia areata (AA) is an autoimmune disease of hair loss affecting people of all ages. Alopecia totalis (AT) and universalis (AU) involve scalp and total body hair loss, respectively. AA significantly affects quality of life, but evidence on the economic burden in adolescents is li...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2022-07-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.36229 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860301994393600 |
|---|---|
| author | Markqayne Ray Elyse Swallow Kavita Gandhi Christopher Carley Vanja Sikirica Travis Wang Nicolae Done James Signorovitch Arash Mostaghimi |
| author_facet | Markqayne Ray Elyse Swallow Kavita Gandhi Christopher Carley Vanja Sikirica Travis Wang Nicolae Done James Signorovitch Arash Mostaghimi |
| author_sort | Markqayne Ray |
| collection | DOAJ |
| description | **Background:** Alopecia areata (AA) is an autoimmune disease of hair loss affecting people of all ages. Alopecia totalis (AT) and universalis (AU) involve scalp and total body hair loss, respectively. AA significantly affects quality of life, but evidence on the economic burden in adolescents is limited.
**Objectives:** To assess healthcare resource utilization (HCRU) and all-cause direct healthcare costs, including out-of-pocket (OOP) costs, of US adolescents with AA.
**Methods:** IBM MarketScan® Commercial and Medicare databases were used to identify patients aged 12-17 years with ≥2 claims with AA/AT/AU diagnosis (prevalent cases), from October 1, 2015, to March 31, 2018, enrolled for ≥12 months before and after the first AA diagnosis (index). Patients were matched 1:3 to non-AA controls on index year, demographics, plan type, and Charlson Comorbidity Index. Per patient per year HCRU and costs were compared post-index.
**Results:** Patients comprised 130 AT/AU adolescents and 1105 non-AT/AU adolescents (53.8% female; mean age, 14.6 years). Post-index, AT/AU vs controls had more outpatient (14.5 vs 7.1) and dermatologist (3.6 vs 0.3) visits, higher mean plan costs ($9397 vs $2267), including medical ($7480 vs $1780) and pharmacy ($1918 vs $487) costs, and higher OOP costs ($2081 vs $751) (all _P_<.001). The non-AT/AU cohort vs controls had more outpatient (11.6 vs 8.0) and dermatologist (3.4 vs 0.4) visits, higher mean plan costs ($7587 vs $4496), and higher OOP costs ($1579 vs $805) (all _P_<.001).
**Discussion:** This large-sample, real-world analysis found that adolescents with prevalent AA had significantly higher HCRU and all-cause costs than matched controls. The greater burden was driven by more frequent outpatient visits, and higher payer medical and pharmacy costs in comparison with controls. Oral corticosteroid use was higher among patients with AT/AU; topical and injectable corticosteroid use was higher for non-AT/AU. Although the data preclude the identification of AA-attributable costs, the matched-control design allows an estimation of incremental all-cause costs associated with AA.
**Conclusions:** Adolescents with AA incurred substantial incremental healthcare costs, with greater costs incurred among those with AT/AU. Study findings suggest that AA incurs costs as a medical condition with a high burden on adolescent patients and health plans. |
| format | Article |
| id | doaj-art-a9cac0f1598c4735ada3c69b6785a621 |
| institution | Kabale University |
| issn | 2327-2236 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-a9cac0f1598c4735ada3c69b6785a6212025-02-10T16:13:32ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362022-07-0192Healthcare Utilization and Costs Among US Adolescents With Alopecia AreataMarkqayne RayElyse SwallowKavita GandhiChristopher CarleyVanja SikiricaTravis WangNicolae DoneJames SignorovitchArash Mostaghimi**Background:** Alopecia areata (AA) is an autoimmune disease of hair loss affecting people of all ages. Alopecia totalis (AT) and universalis (AU) involve scalp and total body hair loss, respectively. AA significantly affects quality of life, but evidence on the economic burden in adolescents is limited. **Objectives:** To assess healthcare resource utilization (HCRU) and all-cause direct healthcare costs, including out-of-pocket (OOP) costs, of US adolescents with AA. **Methods:** IBM MarketScan® Commercial and Medicare databases were used to identify patients aged 12-17 years with ≥2 claims with AA/AT/AU diagnosis (prevalent cases), from October 1, 2015, to March 31, 2018, enrolled for ≥12 months before and after the first AA diagnosis (index). Patients were matched 1:3 to non-AA controls on index year, demographics, plan type, and Charlson Comorbidity Index. Per patient per year HCRU and costs were compared post-index. **Results:** Patients comprised 130 AT/AU adolescents and 1105 non-AT/AU adolescents (53.8% female; mean age, 14.6 years). Post-index, AT/AU vs controls had more outpatient (14.5 vs 7.1) and dermatologist (3.6 vs 0.3) visits, higher mean plan costs ($9397 vs $2267), including medical ($7480 vs $1780) and pharmacy ($1918 vs $487) costs, and higher OOP costs ($2081 vs $751) (all _P_<.001). The non-AT/AU cohort vs controls had more outpatient (11.6 vs 8.0) and dermatologist (3.4 vs 0.4) visits, higher mean plan costs ($7587 vs $4496), and higher OOP costs ($1579 vs $805) (all _P_<.001). **Discussion:** This large-sample, real-world analysis found that adolescents with prevalent AA had significantly higher HCRU and all-cause costs than matched controls. The greater burden was driven by more frequent outpatient visits, and higher payer medical and pharmacy costs in comparison with controls. Oral corticosteroid use was higher among patients with AT/AU; topical and injectable corticosteroid use was higher for non-AT/AU. Although the data preclude the identification of AA-attributable costs, the matched-control design allows an estimation of incremental all-cause costs associated with AA. **Conclusions:** Adolescents with AA incurred substantial incremental healthcare costs, with greater costs incurred among those with AT/AU. Study findings suggest that AA incurs costs as a medical condition with a high burden on adolescent patients and health plans.https://doi.org/10.36469/001c.36229 |
| spellingShingle | Markqayne Ray Elyse Swallow Kavita Gandhi Christopher Carley Vanja Sikirica Travis Wang Nicolae Done James Signorovitch Arash Mostaghimi Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata Journal of Health Economics and Outcomes Research |
| title | Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata |
| title_full | Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata |
| title_fullStr | Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata |
| title_full_unstemmed | Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata |
| title_short | Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata |
| title_sort | healthcare utilization and costs among us adolescents with alopecia areata |
| url | https://doi.org/10.36469/001c.36229 |
| work_keys_str_mv | AT markqayneray healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT elyseswallow healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT kavitagandhi healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT christophercarley healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT vanjasikirica healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT traviswang healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT nicolaedone healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT jamessignorovitch healthcareutilizationandcostsamongusadolescentswithalopeciaareata AT arashmostaghimi healthcareutilizationandcostsamongusadolescentswithalopeciaareata |